ELVElevance Health

Healthcare

$412.79+33% 1Y

$412.79

$277.8952 weeks$430.21

Is it safe?

Good

Strong, no red flags: a safe balance sheet, insiders buying, and comfortable debt (AA).

3 good, 2 neutral, 1 without data

SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Quality6 / 9

Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Insider conviction+$1.4M

Insiders were net buyers (+$1.4M, 90 days to Oct 8, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.

Credit gradeAAderived · Jun 30, 2026

Net cash and profitable. A rule of thumb on leverage, not a credit rating.

Drawdown risk36% volderived · Oct 9, 2026

Moderate price swings, typical volatility. Worst drawdown -50% · now 4% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitymiddle of the market

Max drawdownbetter than 76% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can ELV take a bad year?

Elevance Health holds $4.91B more cash than debt, so a bad year is a question about profits, not about lenders.

$4.91B

Net cash

Net debt / EBITDA: net cash
Net debt / EBITDA · no net borrowings to measure against earnings
Altman Z-score: 3.11
Altman Z-score · safe zone, above 3
Interest cover: 3.79×
Interest cover · operating profit covers the interest bill, with room to spare